Impact of YAQ001 on the gut microbiome, permeability and markers of systemic inflammation in patients with cirrhosis
Jinxia Liu, Fernando García-Guevara, Jane Macnaughtan, Yi Jin, A. Ferret, Frederick Clasen, Ka Y. Yuen, Ramón Garcia Maset, Javier Ramón‐Azcón, Annarein Kerbert, Theo Portlock, Javier Martínez, Abeba Habtesion, Alexandra Phillips, Francesco De Chiara, Ganesh Ingavle, Tomas Baldwin, César Jiménez, Giacomo Zaccherini, Katherine Husi, Miguel Ángel Rodríguez-Gandía, Paul Cordero-Sanchez, Junpei Soeda, Jude A. Oben, Karen Church, Jia V. Li, Aarti Jalan, Adrià Juanola, Elsa Solà, Simon Eaton, Carrie Morgan, Thomas L. Avery, Michał Kowalski, Daniel J. Green, Amir Gander, Lindsey Edwards, I. Jane Cox, Helena Cortez‐Pinto, Reiner Wiest, François Durand, Paolo Caraceni, Roberto Elosúa, Joan Vila, Marco Pavesi, Vicente Arroyo, Nathan Davies, Rajeshwar P. Mookerjee, Víctor Manuel Vargas, Susan Sandeman, Gautam Mehta, Julian R. Marchesi, Agustı́n Albillos, Jennifer Rohn, Fausto Andreola, Saeed Shoaie, Rajiv JalanmedRxiv2025 · DOI
YAQ001 is a novel, highly engineered, non-absorbable, gut-restricted, multiporous, carbon bead adsorbent. Pre-clinical studies and a clinical trial confirmed its therapeutic potential and safety in patients with cirrhosis. The aims of this sub-study were to evaluate the effect of YAQ001 on the gut microbiome and its association with biomarkers of gut permeability and systemic inflammation. In a double-blind randomized trial of 28 patients, YAQ001 (4g daily) or placebo was administered for 12 weeks. Results showed that while overall diversity remained stable, YAQ001 significantly increased beneficial bacteria (e.g., Adlercreutzia equolifaciens) and decreased pathogens (e.g., Klebsiella pneumoniae). Furthermore, YAQ001 reduced microbial virulence factors and antibiotic resistance genes. These shifts correlated with improved gut barrier function and reduced systemic inflammation. In vitro models confirmed YAQ001 prevents K. pneumoniae biofilm formation. These findings suggest YAQ001 exerts its therapeutic effect by favorably modulating the gut ecosystem.
Introduction
In advanced liver cirrhosis, the "gut-liver axis" becomes a primary driver of disease progression. Dysbiosis—a shift toward pathogenic microbial overgrowth—coupled with increased intestinal permeability ("leaky gut") allows bacterial toxins to enter the systemic circulation. This triggers chronic inflammation, which can precipitate organ failure.
Current management often relies on long-term antibiotics, which unfortunately deplete beneficial bacteria and accelerate the global crisis of antimicrobial resistance (AMR). There is a critical need for non-antibiotic therapies that can selectively modulate the gut environment. YAQ001, a non-absorbable carbon bead adsorbent, represents a promising "gut-restricted" approach to sequestering pathogens and toxins without systemic side effects.
Methods
This research was a sub-analysis of the Phase 2 CARBALIVE-SAFETY trial. Twenty-eight patients with cirrhosis were randomized to receive either 4g of YAQ001 daily or a placebo for 12 weeks. The study employed a multi-omics approach to track the biological impact:
Shotgun Metagenomics: Profiling microbial species, virulence factors (VFs), and antibiotic resistance genes (ARGs) using the IGC2 and VFDB databases.
Biomarker Analysis: Measuring serum cytokines (Luminex) and gut permeability via the Lactulose/L-Rhamnose (L/R) ratio.
Metabolomics: Analyzing serum and stool for bile acids and short-chain fatty acids (SCFAs).
In Vitro Modeling: Assessing the impact of YAQ001 on Klebsiella pneumoniae biofilms using a polarized human intestinal epithelial model.
Results
Precision Microbiome Modulation
Unlike broad-spectrum antibiotics, YAQ001 did not significantly alter the overall alpha or beta diversity of the gut microbiome. Instead, it achieved "precision sequestration." The treatment significantly increased the abundance of Adlercreutzia equolifaciens, a beneficial bacterium typically depleted in liver disease. Conversely, it decreased levels of known pathogens associated with poor clinical outcomes, such as Klebsiella pneumoniae and Streptococcus mutans.
Disarming Pathogenicity and Resistance
YAQ001 significantly impacted the functional profile of the microbiome. There was a notable reduction in the expression of virulence factors, including siderophores (iron-acquisition tools), fimbriae (attachment structures), and lipopolysaccharides (pro-inflammatory endotoxins). Crucially, the abundance of antibiotic resistance genes (ARGs) decreased significantly in the YAQ001 group, suggesting a potential to mitigate the "resistome" in these patients.
Clinical Improvements in Permeability and Inflammation
The microbial shifts were accompanied by tangible improvements in host health. The L/R ratio, a gold-standard marker for intestinal permeability, improved significantly in the YAQ001 group compared to placebo. Systemic inflammation markers, including C-reactive protein (CRP), CXCL10, and Angiotensin-Converting Enzyme (ACE)—the latter linked to portal pressure—were also significantly reduced.
Biofilm Prevention
In vitro imaging demonstrated that YAQ001 beads actively bind bacteria to their surface, acting as a competitive binding site. This mechanism effectively prevents pathogens like K. pneumoniae from forming biofilms on the intestinal epithelium, facilitating their removal from the body. In lab models, YAQ001 (10 mg/mL) significantly prevented biofilm formation, outperforming several standard antibiotic concentrations.
Discussion and Conclusion
The results of this sub-study indicate that YAQ001 acts as a "selective sponge," cleaning the gut environment by sequestering pathogens and their invasive machinery. By improving gut barrier integrity and reducing systemic inflammation without the collateral damage of antibiotics, YAQ001 addresses the root causes of gut-liver axis dysfunction.
While the sample size was limited to 28 patients, the consistency across metagenomic, in vitro, and clinical biomarker data supports the further development of YAQ001 as a novel microbiome therapeutic. Future research is needed to optimize dosage and determine if these biomarker improvements translate into long-term prevention of major clinical complications like acute-on-chronic liver failure (ACLF).
Summary updated
Abstract
Abstract Background and aims YAQ001 is a novel, highly engineered, non-absorbable, gut-restricted, multiporous, carbon bead adsorbent. Pre-clinical studies and a clinical trial confirmed its therapeutic potential and safety in patients with cirrhosis. The aims of this sub study were to evaluate the effect of YAQ001 on the gut microbiome and its association with biomarkers of gut permeability and systemic inflammation. Methods In total, 28-patients with cirrhosis were randomized (double-blind) to receive YAQ001 (4g once daily) or Placebo. Gut microbiome and biomarkers of inflammation and gut permeability were assessed at baseline, after 4 and 12-weeks. Changes in biomarkers and relationship with microbiome composition and gene profiling were assessed. The effect of YAQ001 on Klebsiella pneumoniae bacterial biofilms was also assessed using an in vitro gut epithelial model. Results Alpha and beta diversity at different time points were unaltered. YAQ001 increased the abundance of bacteria associated with improved gut health such as Adlercreutzia equolifaciens (p<0.05), a bacterium commonly depleted in liver disease, and decreased the abundance of bacteria associated with infections and poor outcomes such as Klebsiella pneumonia and Streptococcus mutans (p<0.05 each). YAQ001 impacted positively on virulence factors such as siderophores, fimbriae structures and lipopolysaccharides that are associated with inflammation and invasion (p<0.05 each). Antibiotic resistance genes, decreased significantly in the YAQ001 group. These changes were associated with reduction in markers of gut permeability and systemic inflammation with no significant effect on bile acid metabolism. YAQ001 prevented Klebsiella pneumoniae biofilms in vitro . Conclusions The results show that YAQ001 impacts positively on the composition of the microbiome, significantly reduces its virulence, antibiotic resistance genes and biofilm formation, which is associated with modulation of gut permeability and systemic inflammation. Impact and implications YAQ001 exerts its therapeutic effect by favorably modulating the gut ecosystem in cirrhosis. It selectively increases beneficial gut bacteria while suppressing pathogenic taxa linked to adverse outcomes. Beyond composition, YAQ001 reduces microbial virulence by limiting the production of invasive toxins and lowers the abundance of antibiotic-resistance genes. In vitro models also demonstrated its efficacy in inhibiting biofilm formation by key pathogens. In summary, this multifaceted modulation of the microbiome led to tangible clinical improvements, notably enhanced gut barrier function and reduced systemic inflammation. The data support further development of YAQ001 as a novel microbiome therapeutic. Highlights In patients with cirrhosis, YAQ001 specifically enhanced beneficial gut bacteria while suppressing pathogenic bacteria linked to adverse clinical outcomes. YAQ001 significantly reduced the genetic expression of critical virulence factors, including siderophores, fimbriae, and lipopolysaccharides, thereby diminishing the potential for microbial invasion and inflammation. YAQ001 administration led to a significant decrease in the abundance of antibiotic resistance genes within the gut microbiome, potentially restoring therapeutic efficacy of antibiotics. In vitro studies demonstrated that YAQ001 effectively prevents the formation of Klebsiella pneumoniae biofilms, a key mechanism of bacterial persistence and chronic infection. The beneficial microbial shifts were directly associated with clinically relevant improvements in biomarkers of gut permeability and systemic inflammation.
BibTeX
@misc{liu2025impact,
author = {Jinxia Liu and Fernando García-Guevara and Jane Macnaughtan and Yi Jin and A. Ferret and Frederick Clasen and Ka Y. Yuen and Ramón Garcia Maset and Javier Ramón‐Azcón and Annarein Kerbert and Theo Portlock and Javier Martínez and Abeba Habtesion and Alexandra Phillips and Francesco De Chiara and Ganesh Ingavle and Tomas Baldwin and César Jiménez and Giacomo Zaccherini and Katherine Husi and Miguel Ángel Rodríguez-Gandía and Paul Cordero-Sanchez and Junpei Soeda and Jude A. Oben and Karen Church and Jia V. Li and Aarti Jalan and Adrià Juanola and Elsa Solà and Simon Eaton and Carrie Morgan and Thomas L. Avery and Michał Kowalski and Daniel J. Green and Amir Gander and Lindsey Edwards and I. Jane Cox and Helena Cortez‐Pinto and Reiner Wiest and François Durand and Paolo Caraceni and Roberto Elosúa and Joan Vila and Marco Pavesi and Vicente Arroyo and Nathan Davies and Rajeshwar P. Mookerjee and Víctor Manuel Vargas and Susan Sandeman and Gautam Mehta and Julian R. Marchesi and Agustı́n Albillos and Jennifer Rohn and Fausto Andreola and Saeed Shoaie and Rajiv Jalan},
title = {{Impact of YAQ001 on the gut microbiome, permeability and markers of systemic inflammation in patients with cirrhosis}},
year = {2025},
doi = {10.64898/2025.12.01.25341286},
howpublished = {medRxiv},
}